Ï㽶ÊÓƵ

Mallorie B. Heneghan
No Rating Available
(Learn About Our Rating System)

Mallorie B. Heneghan, MD, MS

Languages spoken: English

  • Dr. Heneghan is an Assistant Professor of Pediatrics at the Ï㽶ÊÓƵ of Utah in the Division of Pediatric Hematology/Oncology at Primary Children´s Medical Center. Dr. Heneghan is board-certified in Pediatrics and Pediatric Hematology and Oncology.

    Dr. Heneghan received her medical degree from the Perelman School of Medicine at the Ï㽶ÊÓƵ of Pennsylvania, completed her Pediatric residency at the Children's Hospital of Philadelphia, and her Pediatric Hematology/Oncology Fellowship at Northwestern Ï㽶ÊÓƵ/Ann and Robert H Lurie Children's Hospital of Chicago. She received additional research training earning a Master of Science in Health Services and Outcomes Research from Northwestern Ï㽶ÊÓƵ Feinberg School of Medicine.

    Dr. Heneghan's clinical interest include care of children, adolescents, and young adults with leukemia, lymphoma and various other cancers. Dr. Heneghan's research interests include technology-based interventions, data science, and patient-reported outcomes to predict, monitor, and improve outcomes for children, adolescents, and young adults with hematologic malignancies.

    Specialties

    Board Certification

    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

  • Dr. Heneghan is an Assistant Professor of Pediatrics at the Ï㽶ÊÓƵ of Utah in the Division of Pediatric Hematology/Oncology at Primary Children´s Medical Center. Dr. Heneghan is board-certified in Pediatrics and Pediatric Hematology and Oncology.

    Dr. Heneghan received her medical degree from the Perelman School of Medicine at the Ï㽶ÊÓƵ of Pennsylvania, completed her Pediatric residency at the Children's Hospital of Philadelphia, and her Pediatric Hematology/Oncology Fellowship at Northwestern Ï㽶ÊÓƵ/Ann and Robert H Lurie Children's Hospital of Chicago. She received additional research training earning a Master of Science in Health Services and Outcomes Research from Northwestern Ï㽶ÊÓƵ Feinberg School of Medicine.

    Dr. Heneghan's clinical interest include care of children, adolescents, and young adults with leukemia, lymphoma and various other cancers. Dr. Heneghan's research interests include technology-based interventions, data science, and patient-reported outcomes to predict, monitor, and improve outcomes for children, adolescents, and young adults with hematologic malignancies.

    Board Certification and Academic Information

    Academic Departments Pediatrics -Primary
    Academic Divisions Hematology/Oncology
    Board Certification
    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

    Education history

    Fellowship Pediatrics Hematology, Oncology, and Stem Cell Transplant - Ann & Robert H. Lurie Children's Hospital, Northwestern Ï㽶ÊÓƵ Feinberg School of Medicine Chief Fellow
    Health Services and Outcomes Research - Center for Education in Health Sciences, Northwestern Ï㽶ÊÓƵ Feinberg School of Medicine M.S.
    Fellowship Pediatrics Hematology, Oncology, and Stem Cell Transplant - Ann & Robert H. Lurie Children's Hospital, Northwestern Ï㽶ÊÓƵ Feinberg School of Medicine Fellow
    Pediatrics - Children’s Hospital of Philadelphia Resident
    Professional Medical Medicine - Ï㽶ÊÓƵ of Pennsylvania Perelman School of Medicine M.D.
    Post-Baccalaureate Premedical Certificate - Goucher College Certification
    Undergraduate Psychology - Colgate Ï㽶ÊÓƵ B.A.

    Selected Publications

    Journal Article

    1. Heneghan MB, Castellino SM, Thompson LA (2024). What Is Childhood Lymphoma? JAMA Pediatr. ()
    2. Heneghan MB, Parsons SK, Keller FG, Renfro LA, Pei Q, Rodday AM, Wu Y, Punnett A, Belsky JA, Henderson TO, Kelly KM, Castellino SM (2024). Protocol-Stipulated Dose Modification to Manage Chemotherapy-Induced Peripheral Neuropathy in Children, Adolescents, and Young Adults With High-Risk Hodgkin Lymphoma. JCO Oncol Pract, OP2400089. ()
    3. Newman H, Li Y, Huang YV, Elgarten CW, Myers RM, Ruiz J, Zheng DJ, Leahy AB, Aftandilian C, Arnold SD, Bona K, Gramatges MM, Heneghan MB, Maloney KW, Modi AJ, Mody RJ, Morgan E, Rubnitz J, Winick N, Wilkes JJ, Seif AE, Fisher BT, Aplenc R, Getz KD (2023). Household income and health-related quality of life in children receiving treatment for acute myeloid leukemia: Potential impact of selection bias in health equity research. Cancer Med, 13(7), e6966. ()
    4. King K, Cai S, Barrera L, Reddy P, Heneghan MB, Badawy SM (2023). Barriers to medication adherence in sickle cell disease: A comprehensive theory-based evaluation using the COM-B model. Pediatr Blood Cancer, e30440. ()
    5. Heneghan M, Westphal K, Bergman L, Falkiner R, Filipova L, Geisler S, Kendrich C, Martinez J, Malone S, Haymond S, Callas D, MacQuarrie KL (2021). Closed loop communication using provider team-specific smartphones improves the critical laboratory value notification process in paediatric inpatients. BMJ Open Qual, 10(3). ()
    6. Heneghan MB, Hussain T, Barrera L, Cai SW, Haugen M, Morgan E, Rossoff J, Weinstein J, Hijiya N, Cella D, Badawy SM (2021). Access to Technology and Preferences for an mHealth Intervention to Promote Medication Adherence in Pediatric Acute Lymphoblastic Leukemia: Approach Leveraging Behavior Change Techniques. J Med Internet Res, 23(2), e24893. ()
    7. Heneghan MB, Hussain T, Barrera L, Cai SW, Haugen M, Duff A, Shoop J, Morgan E, Rossoff J, Weinstein J, Hijiya N, Cella D, Badawy SM (2020). Applying the COM-B model to patient-reported barriers to medication adherence in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer, 67(5), e28216. ()
    8. Badawy SM, Shah R, Beg U, Heneghan MB (2020). Habit Strength, Medication Adherence, and Habit-Based Mobile Health Interventions Across Chronic Medical Conditions: Systematic Review. J Med Internet Res, 22(4), e17883. ()
    9. Ramsey WA, Heidelberg RE, Gilbert AM, Heneghan MB, Badawy SM, Alberts NM (2019). eHealth and mHealth interventions in pediatric cancer: A systematic review of interventions across the cancer continuum. Psychooncology, 29(1), 17-37. ()
    10. Heneghan M, Hart J, Dewan M, Wu K, Hope K, Taylor A, Shaw K, Bamat T (2018). No Cause for Alarm: Decreasing Inappropriate Pulse Oximetry Use in Bronchiolitis. Hosp Pediatr. ()
    11. Desai AV, Heneghan MB, Li Y, Bunin NJ, Grupp SA, Bagatell R, Seif AE (2016). Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma. Bone Marrow Transplant, 51(9), 1204-10. ()
    12. Heneghan MB, Rheingold SR, Li Y, Seif AE, Huang YS, McLeod L, Wells L, Fisher BT, Aplenc R (2016). Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk, 16(4), 223-229.e2. ()
    13. Oshrine BR, Olsen MN, Heneghan M, Wertheim G, Daber R, Wilmoth DM, Biegel JA, Pawel B, Aplenc R, King RL (2014). Acquired isochromosome 12p, somatic TP53 and PTEN mutations, and a germline ATM variant in an adolescent male with concurrent acute megakaryoblastic leukemia and mediastinal germ cell tumor. Cancer Genet, 207(4), 153-9. ()
    14. Nagao K, Zhu J, Heneghan MB, Hanson JC, Morasso MI, Tessarollo L, Mackem S, Udey MC (2009). Abnormal placental development and early embryonic lethality in EpCAM-null mice. PLoS One, 4(12), e8543. ()

    Review

    1. Werk RS, Heneghan MB, Badawy SM (2024). Use of Patient-Centered Technology and Digital Interventions in Pediatric and Adult Patients with Hematologic Malignancies. [Review]. Curr Hematol Malig Rep. ()
    2. Heneghan MB, Belsky JA, Milgrom SA, Forlenza CJ (2024). The pediatric approach to Hodgkin lymphoma. [Review]. Semin Hematol, 61(4), 245-252. ()
    3. Zeng XL, Heneghan MB, Badawy SM (2023). Adherence to Oral Chemotherapy in Acute Lymphoblastic Leukemia during Maintenance Therapy in Children, Adolescents, and Young Adults: A Systematic Review. [Review]. Curr Oncol, 30(1), 720-748. ()
    4. Ansari N, Wilson CM, Heneghan MB, Supiano K, Mooney K (2022). How technology can improve communication and health outcomes in patients with advanced cancer: an integrative review. [Review]. Support Care Cancer, 30(8), 6525-6543. ()

  • Clinical Trials